{"schema_version":"1.0","type":"article","title":"瘦瘦針臉垮，乳霜補不回，Galderma先贏","url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra.md","lang":"zh-Hant","date":"2026-10-26","publish_at":"2026-10-26T08:00:00+08:00","updated_at":"2026-10-26","category":"商業分析系列","topic":"商業分析系列","tags":["Ozempic臉","瘦瘦針 臉凹","GLP-1 臉部凹陷","舒顏萃 Sculptra","康霈 CBL-514"],"summary":"打瘦瘦針瘦了，臉也凹了。L'Oréal 忙著找 GLP-1 用戶測乳霜，但少掉的是皮下脂肪，乳霜擦不到。錢正流向針劑：Galderma 填充與刺激劑上半年 +10.5%，AbbVie 喬雅登卻衰退 6.6%。","key_points":["GLP-1 瘦瘦針造成的「Ozempic 臉」流失的是皮下脂肪而非膠原，乳霜補不回；Galderma 2026 全年填充與刺激劑固定匯率成長會維持 8% 以上，AbbVie 的 Juvéderm 全年營收則繼續年減。","Galderma 2026 年上半年填充與刺激劑營收 6.11 億美元、固定匯率成長 10.5%；AbbVie 的 Juvéderm 在 2026 年第二季營收 2.45 億美元、營運年減 6.6%。","KFF 2025 年 11 月調查顯示 18% 美國成年人用過 GLP-1 藥物；BCG 估計處理臉部體積流失與鬆弛的醫美療程五年內會從約 7 億美元成長到 20 億美元。"],"facts":[{"claim":"曾使用過 GLP-1 藥物的美國成年人比例（KFF 調查）","value":18,"unit":"%","as_of":"2025-11-14","source":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"claim":"目前正在使用 GLP-1 藥物的美國成年人比例（KFF 調查）","value":12,"unit":"%","as_of":"2025-11-14","source":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"claim":"50 至 64 歲美國成年人目前使用 GLP-1 的比例","value":22,"unit":"%","as_of":"2025-11-14","source":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"claim":"Galderma 2026 上半年營收","value":3134,"unit":"百萬美元","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma 2026 上半年營收固定匯率成長率","value":24.6,"unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma 2026 全年營收成長預估（固定匯率，上調後）","value":"19–21","unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma 2026 上半年注射美容營收","value":1437,"unit":"百萬美元","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma 2026 上半年填充與刺激劑營收","value":611,"unit":"百萬美元","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma 2026 上半年填充與刺激劑固定匯率成長率","value":10.5,"unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"Galderma 2026 第二季填充與刺激劑固定匯率成長率","value":7.6,"unit":"%","as_of":"2026-07-23","source":"https://www.galderma.com/news/galderma-H12026-performance"},{"claim":"AbbVie 2026 第二季美容營收","value":1282,"unit":"百萬美元","as_of":"2026-07-31","source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"claim":"AbbVie 2026 第二季 Juvéderm 全球營收","value":245,"unit":"百萬美元","as_of":"2026-07-31","source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"claim":"AbbVie 2026 第二季 Juvéderm 營運年增率","value":-6.6,"unit":"%","as_of":"2026-07-31","source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"claim":"Galderma GLP-1 減重病人試驗：九個月時表示臉看起來較不凹陷的比例","value":85.7,"unit":"%","as_of":"2025-07-17","source":"https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss"},{"claim":"Galderma 收購 ZO Skin Health 價格（現金）","value":1.5,"unit":"十億美元","as_of":"2026-10-15","source":"https://www.personalcareinsights.com/news/galderma-zo-skin-health-acquisition.html"},{"claim":"Galderma（含 ZO、Alastin）美國醫師通路保養品市占","value":19,"unit":"%","as_of":"2026-10-15","source":"https://www.personalcareinsights.com/news/galderma-zo-skin-health-acquisition.html"},{"claim":"L'Oréal 2026 上半年皮膚醫學美容部門同店成長率","value":11.3,"unit":"%","as_of":"2026-07-29","source":"https://www.loreal.com/en/press-release/finance/2026-half-year-results/"},{"claim":"BCG 估計臉部體積流失與鬆弛醫美療程五年後市場規模","value":2,"unit":"十億美元","as_of":"2026-10-21","source":"https://uk.fashionnetwork.com/news/Beauty-giants-target-ozempic-face-as-boom-in-obesity-drugs-opens-new-market,1877889.html"},{"claim":"康霈 CBL-514 已完成試驗受試者人數","value":544,"unit":"人","as_of":"2026-05-18","source":"https://www.prnewswire.com/apac/zh/news-releases/-eco-2026--cbl-514--glp-1r---302774493.html"},{"claim":"動物實驗：單用 tirzepatide 停藥後體重回升比例（併用 CBL-514 為 25.2%）","value":55.9,"unit":"%","as_of":"2026-05-18","source":"https://www.prnewswire.com/apac/zh/news-releases/-eco-2026--cbl-514--glp-1r---302774493.html"},{"claim":"康霈 CBL-0201WR 美國二期試驗預計收案人數","value":120,"unit":"人","as_of":"2026-08-31","source":"https://www.caliwaybiopharma.com/news-detail/Caliway_Investor_Conference_Key_Takeaways_20260831/"}],"sections":["01｜臉凹下去，少的是哪一層","02｜同樣賣針劑，Galderma 和喬雅登走向兩邊","03｜保養品巨頭真的押錯了嗎","04｜台灣：康霈把同一個問題倒過來做","參考資料"],"references":[{"title":"Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market","source":"Reuters（FashionNetwork 轉載","date":"2026-10-21","url":"https://uk.fashionnetwork.com/news/Beauty-giants-target-ozempic-face-as-boom-in-obesity-drugs-opens-new-market,1877889.html"},{"title":"Galderma reports record first half 2026 net sales of 3.134 billion USD","source":"Galderma","date":"2026-07-23","url":"https://www.galderma.com/news/galderma-H12026-performance"},{"title":"AbbVie Reports Second-Quarter 2026 Financial Results（Exhibit 99.1","source":"AbbVie／SEC","date":"2026-07-31","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm"},{"title":"Galderma unveils final nine-month data on facial aesthetic changes after medication-driven weight loss","source":"Galderma","date":"2025-07-17","url":"https://www.galderma.com/news/galderma-unveils-final-nine-month-data-medication-driven-weight-loss"},{"title":"Galderma Receives FDA Approval for New SCULPTRA Label","source":"Galderma","date":"2021-12-13","url":"https://www.galderma.com/index.php/news/galderma-receives-fda-approval-new-sculptra-label-offering-more-options-aesthetic-partners"},{"title":"Galderma buys ZO Skin Health for US$1.5B to expand dermatological skin care","source":"Personal Care Insights","date":"2026-10-15","url":"https://www.personalcareinsights.com/news/galderma-zo-skin-health-acquisition.html"},{"title":"2026 Half-Year Results","source":"L'Oréal","date":"2026-07-29","url":"https://www.loreal.com/en/press-release/finance/2026-half-year-results/"},{"title":"KFF Health Tracking Poll: Prescription Drug Costs and GLP-1 Use","source":"KFF","date":"2025-11-14","url":"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/"},{"title":"康霈首登 ECO 2026 口頭發表 CBL-514 併用 GLP-1R 類減重藥物動物數據","source":"康霈生技（PR Newswire","date":"2026-05-18","url":"https://www.prnewswire.com/apac/zh/news-releases/-eco-2026--cbl-514--glp-1r---302774493.html"},{"title":"康霈生技 2026 年下半年線上法說會後重點摘要","source":"康霈生技","date":"2026-08-31","url":"https://www.caliwaybiopharma.com/news-detail/Caliway_Investor_Conference_Key_Takeaways_20260831/"},{"title":"減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？","source":"藥時事","date":"2026-08-31","url":"https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift.html"}],"images":[{"alt":"圖1｜臉凹下去，少的是脂肪層","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra/figure-01.png"},{"alt":"圖2｜同樣賣針劑，兩家走反向","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra/figure-02.png"},{"alt":"圖3｜三家巨頭押的地方不同","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra/figure-03.png"},{"alt":"圖4｜全身一起瘦，還是只瘦肚子","url":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ozempic-face-glp1-facial-volume-galderma-sculptra/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-26）。瘦瘦針臉垮，乳霜補不回，Galderma先贏。https://drugnews.com.tw/articles/2026-10-26-ozempic-face-glp1-facial-volume-galderma-sculptra.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}